Europe — EMA
Obgemsa (Vibegron)
Vibegron, the active ingredient in Obgemsa, is a beta‑3 adrenergic receptor agonist presented as a oral tablet for oral use. It is indicated for the treatment of overactive bladder in adults.
Request sourcing
What is Vibegron?
Vibegron, the active ingredient in Obgemsa, is a beta‑3 adrenergic receptor agonist presented as a oral tablet for oral use. It is indicated for the treatment of overactive bladder in adults. GNH USA supplies Obgemsa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.
GNH USA supplies Obgemsa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.
What is Vibegron used for?
Obgemsa is a beta‑3 adrenergic agonist that works on the urinary bladder smooth muscle to improve storage symptoms.
- Overactive bladder: reduces urgency, frequency and incontinence episodes. - Neurogenic detrusor overactivity: helps control involuntary bladder contractions. - Mixed urinary incontinence: contributes to overall reduction of leak episodes.
What are the side effects of Vibegron?
Adverse reactions reported with vibeuron are generally mild to moderate.
Common Side Effects: - Dry mouth - Headache - Nasal congestion - Constipation - Dizziness - Fatigue
Serious or Rare Side Effects: - Hypertension - Urinary retention - Severe allergic reaction (anaphylaxis) - Elevated liver enzymes - Cardiac arrhythmia - Acute urinary obstruction
What precautions apply to Vibegron?
When prescribing Obgm ... ... ... ... ... ... ... ... … ... … … … … … … … … … … … … … … …
- ... … … … … … … … ... ... ... ... … … ... … … ... … … ... … …
